ArticleInfection and immunity2001
Systemic and mucosal immunizations with fibronectin-binding protein FBP54 induce protective immune responses against Streptococcus pyogenes challenge in mice.
Article in Infection and immunity, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 104 citations in OpenAlex.
- Invasion of pancreatic ductal epithelial cells by Enterococcus faecalis is mediated by fibronectin and enterococcal fibronectin-binding protein A.Scientific reports · 2025Article
- Interplay between group AMicrobiology and molecular biology reviews : MMBR · 2024Review
- Sulfated motifs in heparan sulfate inhibitProteoglycan research · 2023Article
- Group A Streptococcus Infections: Their Mechanisms, Epidemiology, and Current Scope of Vaccines.Cureus · 2022Review
- Pangenome analysis and virulence profiling of Streptococcus intermedius.BMC genomics · 2021Article
- A brief review on Group A Streptococcus pathogenesis and vaccine development.Royal Society open science · 2021Review
- Functional Analysis of a Fibronectin Binding Protein of Streptococcus parasanguinis FW213.Current microbiology · 2020Article
- Immunotherapy targeting the Streptococcus pyogenes M protein or streptolysin O to treat or prevent influenza A superinfection.PloS one · 2020Article
- Review
- Recent Advances in the Development of Peptide Vaccines and Their Delivery Systems Against Group A Streptococcus.Vaccines · 2019Review
- Surfaceome and Proteosurfaceome in Parietal Monoderm Bacteria: Focus on Protein Cell-Surface Display.Frontiers in microbiology · 2018Review
- Contribution of cryptic epitopes in designing a group A streptococcal vaccine.Human vaccines & immunotherapeutics · 2018Article
- Prospective Longitudinal Analysis of Immune Responses in Pediatric Subjects After Pharyngeal Acquisition of Group A Streptococci.Journal of the Pediatric Infectious Diseases Society · 2017Article
- Towards developing a vaccine for rheumatic heart disease.Global cardiology science & practice · 2017Review
- The fibronectin-binding protein Fnm contributes to adherence to extracellular matrix components and virulence of Enterococcus faecium.Infection and immunity · 2015Article
- The fibronectin-binding protein EfbA contributes to pathogenesis and protects against infective endocarditis caused by Enterococcus faecalis.Infection and immunity · 2015Article
- Molecular and genomic characterization of pathogenic traits of group A Streptococcus pyogenes.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2015Review
- Disease manifestations and pathogenic mechanisms of Group A Streptococcus.Clinical microbiology reviews · 2014Review
- Non-invasive monitoring of Streptococcus pyogenes vaccine efficacy using biophotonic imaging.PloS one · 2013Article
- Vaccination against rheumatic heart disease: a review of current research strategies and challenges.Current infectious disease reports · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this study was to examine the suitability of fibronectin-binding protein FBP54 as a putative vaccine for Streptococcus pyogenes infections. When the distribution of the fbp54 gene among the clinical isolates representing various M serotypes was tested by PCR and Southern blot assays, it was found that all of the strains possess this gene. Furthermore, a significant increase in immunoglobulin G (IgG) antibody titers against FBP54 was observed in sera from patients with S. pyogenes infections compared with those from healthy volunteers (P < 0.005). Mice were immunized with FBP54 subcutaneously, orally, or nasally. An enzyme-linked immunosorbent assay revealed that antigen-specific IgG antibodies were induced in the sera of immunized mice, while high salivary levels of IgA antibodies were detected after oral and nasal immunizations. Mice subcutaneously or orally immunized with FBP54 survived significantly longer following the challenge with S. pyogenes than did nonimmunized mice (P < 0.001). These results indicate that FBP54 is a promising vaccine for the prevention of S. pyogenes infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.